Bluestone JA - Search Results

1

Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis.

Lee JC, Mehdizadeh S, Smith J, Young A, Mufazalov IA, Mowery CT, Daud A, Bluestone JA. Lee JC, et al. Among authors: bluestone ja. Sci Immunol. 2020 Oct 2;5(52):eaba0759. doi: 10.1126/sciimmunol.aba0759. Sci Immunol. 2020. PMID: 33008914 Free PMC article.

2

Natural versus adaptive regulatory T cells.

Bluestone JA, Abbas AK. Bluestone JA, et al. Nat Rev Immunol. 2003 Mar;3(3):253-7. doi: 10.1038/nri1032. Nat Rev Immunol. 2003. PMID: 12658273 Review.

3

Regulatory T-cell therapy: is it ready for the clinic?

Bluestone JA. Bluestone JA. Nat Rev Immunol. 2005 Apr;5(4):343-9. doi: 10.1038/nri1574. Nat Rev Immunol. 2005. PMID: 15775994 Review.

4

Clinical application of regulatory T cells for treatment of type 1 diabetes and transplantation.

Brusko T, Bluestone J. Brusko T, et al. Eur J Immunol. 2008 Apr;38(4):931-4. doi: 10.1002/eji.200738108. Eur J Immunol. 2008. PMID: 18395864 Free article.

5

The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.

DuPage M, Chopra G, Quiros J, Rosenthal WL, Morar MM, Holohan D, Zhang R, Turka L, Marson A, Bluestone JA. DuPage M, et al. Among authors: bluestone ja. Immunity. 2015 Feb 17;42(2):227-238. doi: 10.1016/j.immuni.2015.01.007. Epub 2015 Feb 10. Immunity. 2015. PMID: 25680271 Free PMC article.

6

Targeting Treg signaling for the treatment of autoimmune diseases.

Spence A, Klementowicz JE, Bluestone JA, Tang Q. Spence A, et al. Among authors: bluestone ja. Curr Opin Immunol. 2015 Dec;37:11-20. doi: 10.1016/j.coi.2015.09.002. Epub 2015 Sep 29. Curr Opin Immunol. 2015. PMID: 26432763 Free PMC article. Review.

7

Shifting the Evolving CAR T Cell Platform into Higher Gear.

Holohan DR, Lee JC, Bluestone JA. Holohan DR, et al. Among authors: bluestone ja. Cancer Cell. 2015 Oct 12;28(4):401-402. doi: 10.1016/j.ccell.2015.09.014. Cancer Cell. 2015. PMID: 26461084 Free article.

8

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

Bluestone JA, Buckner JH, Fitch M, Gitelman SE, Gupta S, Hellerstein MK, Herold KC, Lares A, Lee MR, Li K, Liu W, Long SA, Masiello LM, Nguyen V, Putnam AL, Rieck M, Sayre PH, Tang Q. Bluestone JA, et al. Sci Transl Med. 2015 Nov 25;7(315):315ra189. doi: 10.1126/scitranslmed.aad4134. Sci Transl Med. 2015. PMID: 26606968 Free PMC article. Clinical Trial.

9

Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease.

DuPage M, Bluestone JA. DuPage M, et al. Among authors: bluestone ja. Nat Rev Immunol. 2016 Mar;16(3):149-63. doi: 10.1038/nri.2015.18. Epub 2016 Feb 15. Nat Rev Immunol. 2016. PMID: 26875830 Free article. Review.

10

FOXP3, the Transcription Factor at the Heart of the Rebirth of Immune Tolerance.

Bluestone JA. Bluestone JA. J Immunol. 2017 Feb 1;198(3):979-980. doi: 10.4049/jimmunol.1602060. J Immunol. 2017. PMID: 28115585 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

537 results

Search Page

Filters